Equibles does not estimate personal net worth.
Get an email with a short summary when Corcept Therapeutics Inc publishes a filing, an earnings call transcript or a press release.
Get CORT alertsAtabak Mokari is recorded as CFO at Corcept Therapeutics Inc (CORT). The newest filing on record that lists Atabak Mokari as CFO at Corcept Therapeutics Inc (CORT) is dated April 17, 2026. The proxy statement of Corcept Therapeutics Inc reports total compensation of $6,135,667 for Atabak Mokari in fiscal 2025, including a base salary of $566,347. Disclosed compensation is on record for 5 fiscal years. Atabak Mokari has spoken on 22 earnings calls across 1 company, most recently for Corcept Therapeutics Inc on July 29, 2026. Corcept Therapeutics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Corcept Therapeutics Inc includes Joseph K. Belanoff (CEO and Board Member), James N. Wilson (Chairman and Board Member), Joshua M. Murray (CFO, Head of Investor Relations and Board Member) and 7 others.
“Today, we issued a press release announcing our financial results for the second quarter and providing a corporate update. The copy is available at Corsep.com. Our complete financial results will be available when we file our 401k with the SEC.”
“Today, we issued a press release announcing our financial results for the first quarter and providing a corporate update. A copy is available at coursehub.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.”
“Today, we issued a press release announcing our financial results for the full year and providing a corporate update. The copy is available at Corsep.com. Our complete financial results will be available when we file our Form 10-K with the SEC.”
“Today, we issued a press release announcing our financial results for the third quarter and providing a corporate update. The copy is available at courseup.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.”
“Thank you. expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied.”
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Corcept Therapeutics Inc (CORT) | Chief Financial Officer and Treasurer | $566,347 | $6,135,667 |
| 2024 | Corcept Therapeutics Inc (CORT) | Chief Financial Officer and Treasurer | $546,323 | $3,857,306 |
| 2023 | Corcept Therapeutics Inc (CORT) | Chief Financial Officer and Treasurer | $524,333 | $3,717,107 |
| 2022 | Corcept Therapeutics Inc (CORT) | Chief Financial Officer and Treasurer | $492,750 | $1,888,637 |
| 2021 | Corcept Therapeutics Inc (CORT) | Chief Financial Officer and Treasurer | $390,000 | $7,021,639 |
